Anemia

Phase I trial of Hematide initiated

Published in Cancer Weekly, November 2nd, 2004

Affymax, Inc., announced that it has initiated a placebo controlled, phase I dose-finding clinical trial with its lead product candidate, Hematide, a peptide-based erythropoiesis stimulating agent (ESA) that has been designed to stimulate production of red blood cells.

The goals of this trial are to evaluate the safety and pharmacokinetics of Hematide and to determine its effect on reticulocytes and hemoglobin. Results of this trial are expected in early 2005, and, if positive, will allow Affymax to enter into phase II safety and efficacy trials later that year.

Hematide is a synthetic peptide ESA that has been shown to stimulate the production of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-11-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry